Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is Investigating Replimune --> Accessibility: Skip TopNav Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm August 05, 2026 17:52 ET | Source: Bragar Eagel & Squire Bragar Eagel & Squire If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648. Click here to participate in the action. NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ:REPL) on behalf of Replimune stockholders. Our investigation concerns whether Replimune has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: On July 28, 2026, the US Food and Drug Administration ("FDA") released briefing documents related to Replimune's lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents state the FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of the drug as "not interpretable." The assessment used in the study "confounds interpretation of the reported efficacy results and limits FDA's ability to verify the reported results," the FDA reviewers said. Following this news, Replimune's stock price dropped $3.27, or 37.89% in intraday trading on July 28, 2026. Next Steps: If you purchased or otherwise acquired Replimune shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , by telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn and Facebook , and keep up with other news by following Brandon Walker, Esq. on LinkedIn . Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 [email protected] www.bespc.com Tags Replimune REPL class action investigation Brandon Walker Bragar Eagel & Squire BES Melissa Fortunato lawsuit fraud loss stock drop Class Action GlobeNewswire Recommended Reading August 05, 2026 16:57 ET | Source: Bragar Eagel & Squire BLAIZE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Blaize Holdings, Inc. and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Blaize (BZAI) To Contact Him Directly To Discuss Their Options If you purchased or... Read More August 05, 2026 16:38 ET | Source: Bragar Eagel & Squire COGENT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cogent Communications Holdings, Inc. and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Cogent (CCOI) To Contact Him Directly To Discuss Their Options If you purchased or... Read More